Assenagon Asset Management S.A. Raises Stock Holdings in Lantheus Holdings, Inc. $LNTH

Key Points

• Assenagon Asset Management increased its Lantheus stake by 440.3% in the second quarter, owning 714,980 shares valued at approximately $79.3 million. Institutional investors collectively own 99.06% of LNTH.
• Analyst sentiment is mixed: TD Cowen and Truist Financial downgraded Lantheus to “hold,” while other firms maintained “outperform” or “buy” ratings. The consensus rating is “Hold,” with an average price target of $108.11.
• Lantheus exceeded quarterly expectations, reporting adjusted earnings of $1.55 per share versus a $1.30 consensus estimate and revenue of $388.18 million versus $363.23 million expected. Revenue rose 2.7% year over year.

Assenagon Asset Management S.A. raised its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 440.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 714,980 shares of the medical equipment provider's stock after purchasing an additional 582,661 shares during the quarter. Assenagon Asset Management S.A. owned 1.10% of Lantheus worth $79,320,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of LNTH. Western Wealth Management LLC bought a new position in shares of Lantheus during the first quarter worth $25,000. Osterweis Capital Management Inc. bought a new stake in shares of Lantheus in the second quarter worth about $36,000. Smartleaf Asset Management LLC lifted its position in shares of Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider's stock worth $34,000 after buying an additional 197 shares in the last quarter. Bessemer Group Inc. boosted its stake in Lantheus by 221.2% during the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider's stock valued at $39,000 after buying an additional 354 shares during the last quarter. Finally, Parallel Advisors LLC grew its holdings in Lantheus by 122.6% during the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider's stock valued at $36,000 after buying an additional 298 shares in the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on the stock. TD Cowen lowered shares of Lantheus from a "buy" rating to a "hold" rating and lowered their price objective for the company from $110.00 to $102.50 in a research report on Monday. Mizuho reduced their price objective on Lantheus from $120.00 to $115.00 and set an "outperform" rating on the stock in a research note on Wednesday, July 29th. Citizens Jmp restated a "market outperform" rating and set a $115.00 price objective on shares of Lantheus in a research report on Monday, June 29th. Citigroup reiterated an "outperform" rating on shares of Lantheus in a report on Friday, May 8th. Finally, Truist Financial lowered Lantheus from a "buy" rating to a "hold" rating and decreased their price target for the company from $125.00 to $102.50 in a report on Monday. Five investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $108.11.

Lantheus Stock Performance

Lantheus stock opened at $100.95 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.64 and a current ratio of 3.06. The company has a market capitalization of $6.57 billion, a PE ratio of 24.38 and a beta of -0.03. The company has a 50 day moving average price of $104.09 and a 200-day moving average price of $87.98. Lantheus Holdings, Inc. has a fifty-two week low of $49.67 and a fifty-two week high of $111.86.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, topping the consensus estimate of $1.30 by $0.25. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The company had revenue of $388.18 million for the quarter, compared to the consensus estimate of $363.23 million. During the same period last year, the business posted $1.57 EPS. Lantheus's quarterly revenue was up 2.7% on a year-over-year basis. As a group, equities analysts forecast that Lantheus Holdings, Inc. will post 4.5 earnings per share for the current year.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company's portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source